Xiaoqing Fu

Featured in: Favicon

optica.org Favicon

jacionline.org Favicon

jrheum.org Favicon

annallergy.org Favicon

spectroscopyonline.com Favicon

biorxiv.org Favicon

onlinelibrary.wiley.com Favicon

Articles

Development and Validation of a Simulation Model for Treatment to Maintain Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Aug 29, 2023 | acrjournals.onlinelibrary.wiley.com | Zachary S. Wallace |John Stone |Xiaoqing Fu |Peter A. Merkel

Objective Fixed and tailored rituximab retreatment strategies to maintain remission in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) are associated with tradeoffs. The current study was undertaken to develop a simulation model (AAV-Sim) to project clinical outcomes with these strategies. Methods We developed the AAV-Sim, a microsimulation model of clinical events among individuals with AAV initiating treatment to maintain remission.
Comparative Effectiveness of Rituximab‐ Versus Cyclophosphamide‐Based Remission Induction Strategies in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis for the Risk of Kidney Failure and Mortality - Wallace - Arthritis & Rheumatology - Wiley

Aug 8, 2023 | acrjournals.onlinelibrary.wiley.com | Zachary S. Wallace |Rheumatology Unit |Xiaoqing Fu |Claire Cook

Full Length The data reported herein have been supplied by the United States Renal Data System (USRDS). The interpretation and reporting of these data are the responsibility of the authors and do not represent the official policy or interpretation of the US Government. Dr. Wallace is supported by the NIH/NIAMS (grants K23AR073334 and R03AR078938) and the Rheumatology Research Foundation (award K Supplement).

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →